Last updated: May 28, 2026
Rapamune suppliers landscape hinges on two different supply chains: (1) original manufacturer and key contractors for the brand drug, and (2) generic and biosimilar-analog supply for everolimus (Rapamune’s therapeutic class does not have a biosimilar concept, but there is a broad generic small-molecule market). Rapamune is a sirolimus product; the market’s “supplier” question splits into the company manufacturing the finished drug (and licensed packagers/labelers), plus upstream API and sterile fill-finish or tablet production contractors for sirolimus formulations.
Rapamune (sirolimus) suppliers: who manufactures the brand drug today?
Rapamune is marketed by Pfizer in many jurisdictions historically. The finished-dose manufacturing supply is typically executed through Pfizer’s internal manufacturing sites or third-party contract manufacturing organizations (CMOs) that produce and package the finished product under Pfizer’s quality system.
What to look for on-label to identify Rapamune suppliers (finished drug)
- Applicant / labeler listed on FDA packaging for U.S. products
- Manufacturer name and address for the drug product (on the carton/blister/bottle labeling)
- NDC-specific manufacturer details, since labeler/manufacturer can vary by strength and package
Key supplier categories
- Drug product manufacturer (CMO or internal): tablets/capsules (depending on strength/formulation), blister/bottle packaging.
- Packager/labeler: sometimes a separate entity when U.S. distribution uses repack/label partners.
- API supplier: sirolimus active pharmaceutical ingredient produced by API manufacturers and then supplied to the drug product manufacturer.
- Specialized formulation contractors: for liquid or bioavailability-sensitive formats, sterile or non-sterile fill-finish may be handled by specific CMOs. (Rapamune has historically been supplied as tablets/capsules depending on country and historical listing.)
Which companies supply sirolimus (Rapamune API) to drug product manufacturers?
“Supplier” for API is usually established through:
- Pfizer’s quality agreements and DMFs for the sirolimus API
- commercial API sourcing tied to NDA/ANDA supply chains
- cGMP-reviewed supply arrangements
How API supplier identification is typically evidenced in practice
- US DMF referencing in the application package (API manufacturer listed under the DMF)
- Pre-approval inspections and quality/CMC filings that name manufacturing sites
- Labeling that lists the drug substance manufacturer for some markets
Because API manufacturing and DMF referencing can change by site, supplier lists are best tied to specific NDCs/strengths and time windows.
What contract manufacturing organizations (CMOs) make Rapamune for Pfizer or licensees?
CMO involvement is common for specialty oral small molecules and can include:
- tablet/capsule manufacturing (blending, granulation if applicable, compression, coating, encapsulation)
- packaging (bottling, blistering) and labeling
- stability testing and batch-release testing through contracted labs (less often on-label)
Operational reality
- Finished product CMO assignments can differ by strength and by revision of manufacturing changes.
- Packaging partners can change more frequently than the API supply base.
Do Rapamune suppliers differ by jurisdiction (US vs EU vs other markets)?
Yes. Labeler/manufacturer and packager identities can vary by:
- local marketing authorization holder and division of supply responsibilities
- tariff and logistics-driven sourcing
- local GMP site capabilities and regulatory inspection outcomes
For investors and license strategists, the practical approach is to map supply by:
- country-specific SmPC or packaging labeling
- local NCA authorization dossiers
- local NDC/PL/MAH listings where applicable
How can you map Rapamune suppliers using FDA NDC and labeling data?
A reliable “supplier mapping” workflow uses:
- Pull the NDC by strength and dosage form for the relevant Rapamune product.
- Check the active labeler/manufacturer line items.
- Cross-check the manufacturer site for the drug product.
- Match the site to likely CMO/tablet line capability or to known Pfizer manufacturing networks.
Outputs you can make
- NDC-to-manufacturer mapping table
- which strength(s) are sourced from which facility
- packaging partner mapping
- stability/release site (where disclosed)
What supplier risk exists for Rapamune (single-site vs multi-site manufacturing)?
Supplier risk depends on:
- whether Pfizer uses multiple manufacturing sites for drug product
- whether the product is supplied through limited-availability CMO capacity
- API continuity for sirolimus (high-potency compound handling requirements)
Common risk signals in the market:
- repeated site changes in labeling history
- manufacturing change control filings
- product discontinuation notices or shortages tied to batch failures
How do Rapamune suppliers compare with generic sirolimus suppliers?
Generic sirolimus products are supplied by:
- multiple ANDA applicants
- diverse CMO networks
- different tablet/capsule formulations (bioequivalence depends on formulation and manufacturing controls)
Supplier comparison lens
- Rapamune brand: fewer, more stable supplier relationships under Pfizer’s control
- Generics: wider supplier base, but more volatility in CMO assignments and launch-era supply chain builds
From a procurement standpoint, this means:
- branded supply often has fewer vendors
- generic supply often has more vendors, which can reduce single-source exposure
Which suppliers matter most for ongoing Rapamune supply stability?
The operational bottlenecks are usually:
- sirolimus API supply continuity (potency, impurity profiles, and validated processes)
- drug product potency/quality control release capacity
- tablet/capsule line availability and the ability to respond to batch failures
For business planning, prioritize:
- identified drug product manufacturing sites
- whether multiple sites are qualified
- API sourcing breadth and whether the API is under a small number of DMF holders
Key Takeaways
- Rapamune supply is best treated as two-layer sourcing: finished drug product manufacturers (and packagers/labelers) plus upstream sirolimus API suppliers.
- “Supplier” differs by strength, NDC, and country because labeler and manufacturing site names vary across listings and time.
- The highest supply-chain leverage points are API continuity for sirolimus and validated drug product manufacturing capacity with robust release testing.
- Generic sirolimus supply typically has more vendors, which can reduce single-source risk versus the branded chain, though it can increase variability in manufacturing contractors.
FAQs
- What are the key names to look for on Rapamune packaging to identify the manufacturer?
- How do I map Rapamune suppliers by NDC for each strength and dosage form?
- Does rapamycin/sirolimus API supply come from a single global source?
- Can contract manufacturers change between Rapamune batch productions without changing the labeler?
- How does supplier risk differ between brand Rapamune and generic sirolimus tablets or capsules?
References
- FDA Orange Book. “Rapamune” (sirolimus) product listings and application references. FDA. (Accessed 2026).
- FDA Labeling and NDC directories for “Rapamune” (sirolimus). U.S. Food and Drug Administration. (Accessed 2026).
